Searching for the Causal Variants of the Association Between Hypertriglyceridemia and the Genome-Wide Association Studies-Derived Signals? Take a Look in the Native American Populations.
Carlos A Aguilar-Salinas, Magdalena Del Rocío Sevilla González, María Teresa Tusie-Luna
{"title":"Searching for the Causal Variants of the Association Between Hypertriglyceridemia and the Genome-Wide Association Studies-Derived Signals? Take a Look in the Native American Populations.","authors":"Carlos A Aguilar-Salinas, Magdalena Del Rocío Sevilla González, María Teresa Tusie-Luna","doi":"10.1161/CIRCGENETICS.117.002010","DOIUrl":null,"url":null,"abstract":"Genome-wide association studies (GWAS) have made possible the identification of >175 loci that affect plasma lipid levels. Its results have been crucial to identify roles of new players in lipid metabolism (ie, apolipoprotein A5) or even to postulate potential treatment targets (ie, apolipoprotein C-III). However, a large proportion of the GWAS results has not been translated in clinically useful information because a large proportion of responsible single nucleotide polymorphisms (SNPs) are located either in noncoding regions or in genes without an obvious participation in any metabolic pathway.1 This is the case of the association between rs964184 and plasma triglycerides concentrations. This highly significant association has been a constant finding in the GWAS reports, regardless the sample size or the study sample composition.2 The frequency of the risk allele (G) varies between populations from 12% in whites to 27% in Mexicans. Also, it is common in Japanese (31%) and in Native American communities located in Central Mexico (≈50%). This SNP is nearby the 3′ untranslated region of the zinc finger gene ( ZPR1 ) and close to APOA5 . However, the identification of the functional variant that explains the association has not been possible.\n\nSee Article by Hsueh et al \n\nThe study of ethnic groups not included in the discovery cohorts, some methodological approaches (ie, admixture mapping or inception by descent [IBD] mapping), and deep genotyping are among the potential approaches to identify the variants responsible for a GWAS signal.3 The study of the Native American populations is an option because this group has not included in the majority of the lipids-related GWAS. The greater susceptibility of the populations derived from the Native American founding groups for having hypertriglyceridemia is well documented.4 These groups include the Amerindian communities living in Canada and the United States, mestizos living in the …","PeriodicalId":10277,"journal":{"name":"Circulation: Cardiovascular Genetics","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1161/CIRCGENETICS.117.002010","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Circulation: Cardiovascular Genetics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1161/CIRCGENETICS.117.002010","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Genome-wide association studies (GWAS) have made possible the identification of >175 loci that affect plasma lipid levels. Its results have been crucial to identify roles of new players in lipid metabolism (ie, apolipoprotein A5) or even to postulate potential treatment targets (ie, apolipoprotein C-III). However, a large proportion of the GWAS results has not been translated in clinically useful information because a large proportion of responsible single nucleotide polymorphisms (SNPs) are located either in noncoding regions or in genes without an obvious participation in any metabolic pathway.1 This is the case of the association between rs964184 and plasma triglycerides concentrations. This highly significant association has been a constant finding in the GWAS reports, regardless the sample size or the study sample composition.2 The frequency of the risk allele (G) varies between populations from 12% in whites to 27% in Mexicans. Also, it is common in Japanese (31%) and in Native American communities located in Central Mexico (≈50%). This SNP is nearby the 3′ untranslated region of the zinc finger gene ( ZPR1 ) and close to APOA5 . However, the identification of the functional variant that explains the association has not been possible.
See Article by Hsueh et al
The study of ethnic groups not included in the discovery cohorts, some methodological approaches (ie, admixture mapping or inception by descent [IBD] mapping), and deep genotyping are among the potential approaches to identify the variants responsible for a GWAS signal.3 The study of the Native American populations is an option because this group has not included in the majority of the lipids-related GWAS. The greater susceptibility of the populations derived from the Native American founding groups for having hypertriglyceridemia is well documented.4 These groups include the Amerindian communities living in Canada and the United States, mestizos living in the …
期刊介绍:
Circulation: Genomic and Precision Medicine considers all types of original research articles, including studies conducted in human subjects, laboratory animals, in vitro, and in silico. Articles may include investigations of: clinical genetics as applied to the diagnosis and management of monogenic or oligogenic cardiovascular disorders; the molecular basis of complex cardiovascular disorders, including genome-wide association studies, exome and genome sequencing-based association studies, coding variant association studies, genetic linkage studies, epigenomics, transcriptomics, proteomics, metabolomics, and metagenomics; integration of electronic health record data or patient-generated data with any of the aforementioned approaches, including phenome-wide association studies, or with environmental or lifestyle factors; pharmacogenomics; regulation of gene expression; gene therapy and therapeutic genomic editing; systems biology approaches to the diagnosis and management of cardiovascular disorders; novel methods to perform any of the aforementioned studies; and novel applications of precision medicine. Above all, we seek studies with relevance to human cardiovascular biology and disease.